Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients
Yusuke Omura, Yuji Toiyama, Yoshinaga Okugawa, et al.
Cancer Immunology Immunotherapy (2020) Vol. 69, Iss. 12, pp. 2533-2546
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Somayeh Vafaei, Angelina Olegovna Zekiy, Ramadhan Ado Khanamir, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 167
Predictive biomarkers of colon cancer immunotherapy: Present and future
Wanting Hou, Yi Cheng, Hong Zhu
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 89
Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases
Christian Bailly, Xavier Thuru, Bruno Quesnel
Cancers (2021) Vol. 13, Iss. 12, pp. 3034-3034
Open Access | Times Cited: 97
Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine
Afshin Derakhshani, Shahryar Hashemzadeh, Zahra Asadzadeh, et al.
Cancers (2021) Vol. 13, Iss. 10, pp. 2414-2414
Open Access | Times Cited: 72
Immunotherapy and immunoevasion of colorectal cancer
Mohammad Al Zein, Mona Boukhdoud, Hadi Shammaa, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 9, pp. 103669-103669
Closed Access | Times Cited: 26
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies
Stephanie Pitts, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 8
Soluble B7 and TNF family in colorectal cancer: Serum level, prognostic and treatment value
Mina Monfared, Sina Nazmi, Forough Parhizkar, et al.
Human Immunology (2025) Vol. 86, Iss. 2, pp. 111232-111232
Closed Access | Times Cited: 1
Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges
Alessandro Poggi, Maria Raffaella Zocchi
Molecular Therapy — Oncolytics (2021) Vol. 24, pp. 26-42
Open Access | Times Cited: 38
PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application
Luca Mastracci, Federica Grillo, Paola Parente, et al.
Pathologica (2022) Vol. 114, Iss. 5, pp. 352-364
Open Access | Times Cited: 25
Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer
Yinjun He, Xiang Zhang, Ming Zhu, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 16
Exosomes-delivered PD-L1 siRNA and CTLA-4 siRNA protect against growth and tumor immune escape in colorectal cancer
Jian Li, Yuxiang Chen, Mingmei Liao, et al.
Genomics (2023) Vol. 115, Iss. 4, pp. 110646-110646
Open Access | Times Cited: 16
TIM3 and CTLA4 immune checkpoint polymorphisms are associated with acute myeloid leukemia in Saudi Arabia
Mashael Alqahtani, Ali Aljuaimlani, Jameel Al‐Tamimi, et al.
Hematology (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 5
Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer
Ketao Jin, Bo Chen, Yu‐Yao Liu, et al.
Cancer Cell International (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 32
Abnormal alternative splicing promotes tumor resistance in targeted therapy and immunotherapy
Kun Deng, Jingwei Yao, Jialu Huang, et al.
Translational Oncology (2021) Vol. 14, Iss. 6, pp. 101077-101077
Open Access | Times Cited: 28
Targeted Therapies in Colorectal Cancer: Recent Advances in Biomarkers, Landmark Trials, and Future Perspectives
João Manzi, Camilla O. Hoff, Raphaella Ferreira, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 3023-3023
Open Access | Times Cited: 12
CTLA-4: Checkpoints beyond the membrane
Sarah L. Buchan
Molecular Therapy (2024) Vol. 32, Iss. 2, pp. 279-281
Open Access | Times Cited: 4
Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications
Lin Chen, Yuqing Chao, Wenjing Li, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 4
Clinical Relevance of Soluble Forms of Immune Checkpoint Molecules sPD-1, sPD-L1, and sCTLA-4 in the Diagnosis and Prognosis of Ovarian Cancer
Janina Świderska, Mateusz Kozłowski, Katarzyna Nowak, et al.
Diagnostics (2022) Vol. 12, Iss. 1, pp. 189-189
Open Access | Times Cited: 14
PD-L1 Expression in Colorectal Adenocarcinoma Is Associated With the Tumor Immune Microenvironment and Epithelial-Mesenchymal Transition
İlke Evrim SEÇİNTİ, Tümay Özgür, İsa Dede
American Journal of Clinical Pathology (2022) Vol. 158, Iss. 4, pp. 506-515
Closed Access | Times Cited: 13
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy
Andrea Botticelli, Giulia Pomati, Alessio Cirillo, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 13
Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment
Meiling Yang, Ciqiu Yang, Dong Ma, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 7
Integration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment
Shiya Yao, Yuejun Han, Mengxiang Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Effects of Apatinib combined with Temozolomide on levels of sPD-1 and sPD-L1 in patients with drug-resistant recurrent glioblastoma
Ren Zhao Kuang, Jun Wang, Y. Wang, et al.
Clinics (2024) Vol. 79, pp. 100376-100376
Open Access | Times Cited: 2
Interplay of stromal tumor-infiltrating lymphocytes, normal colonic mucosa, cancer-associated fibroblasts, clinicopathological data and the immunoregulatory molecules of patients diagnosed with colorectal cancer
Łukasz Zadka, Mariusz Chabowski, Damian Grybowski, et al.
Cancer Immunology Immunotherapy (2021) Vol. 70, Iss. 9, pp. 2681-2700
Open Access | Times Cited: 15
Role of Ezrin/Radixin/Moesin in the Surface Localization of Programmed Cell Death Ligand-1 in Human Colon Adenocarcinoma LS180 Cells
Takuro Kobori, Chihiro Tanaka, Mayuka Tameishi, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 9, pp. 864-864
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top